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The inherent resistance of human solid tumours to
cancer chemotherapy is a major problem in medical
oncology. Experimentally, in cell lines, the resis-
tance phenomena studied are often induced by a
process analogous to the induction of antibiotic
resistance in bacteria. The acquired mechanisms by
which resistant mutants differ from parent cells are
studied and less attention paid to the differences
between the innate resistance of a tumour and the
normal cell population from which it arose. There
is an urgent need to relate the results obtained in
these systems to human tumour tissue.
Verapamil, a calcium transport antagonist widely
used in cardiological medicine, has been shown to
be a potent modifier of vincristine resistance in
several cell lines (Tsuruo et al., 1981 & 1983).
Clinical trials using verapamil as a modifier of
vindesine therapy in advanced human malignancy
are in progress (Cantwell et al., 1985). In the
present study we have examined the effects of
verapamil on the sensitivity of primary human
colonic carcinomata to vincristine.
In the formal stathmokinetic experiment a dose
of vincristine is administered, large relative to
clinical therapy (i.e. approximately 15 times greater
for human colon cancer), to arrest all dividing cells
in metaphase. The resulting "arrested metaphase"
figures are easily recognised in histological
preparations, and their rate of accumulation is used
to calculate the cell birth rate. Using this technique
we have previously demonstrated that a six times
greater dose of vincristine is required to achieve a
maximum rate of metaphase accumulation in
human colonic tumour tissue than that required for
normal colonic mucosa (Pritchett et al., 1982). We
have recently developed a method of measuring
directly the degree of escape from metaphase arrest
by counting the proportion of mitotic figures
showing anaphase or telophase configuration (Ince
et al., 1985). The resulting Post-Metaphase Index
(PMI) can be used in a "dose-response" format at a
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range of-vincristine doses extending down to the
human therapeutic range (i.e. 200-300nmol plasma
levels,). This is the technique we have used in
assessing changes in vincristine resistance in the
present study.
Eleven human colorectal carcinomata were
studied. All were left-sided lesions treated by
abdominoperineal resection, anterior resection, or
left hemicolectomy. The specimens were collected
and cleaned in theatre, and transported to the
laboratory in ice-cold medium. Apparently viable
areas of tumour tissue were identified, from which
explants, measuring -2mm3, were prepared. The
explants were placed on millipore filters in 60mm
plastic petri dishes and were cultured in Wey-
mouth's MB752/1 medium supplemented with 10%
foetal calf serum, hydrocortisone, vitamin C, and
ferrous sulphate. The dishes were maintained in a
controlled atmosphere chamber with a gas phase of
95% 02' 5% CG2, using a rocking culture
technique (Senior et al., 1984).
Altogether 120 explants per tumour were used
with four explants to each dish. After 16h
incubation the dishes were divided into three
groups and the medium was changed to include
verapamil at one of three doses viz. 0.0 imol,
6.6 imol, 13.2 umol. After a further 2h the media
were again changed to include verapamil at the
same dose and vincristine at one of five doses,
viz. 270nmol, 540nmol, 1080nmol, 2160nmol,
4320nmol. After 2h incubation with vincristine the
tissues were fixed in formalin and routinely
processed to paraffin wax. Histological sections
were prepared at 4gm and stained with haematoxylin
and eosin.
The PMI was derived by evaluating a total of at
least 50 tumour cell mitotic figures in step sections
of each explant. Multiples of a whole section of
each explant were counted including that in which
the 50th mitosis was identified. The proportion of
post-metaphase mitotic figures was recorded. At
each combination of verapamil and vincristine
doses the data from the several explants were
pooled to provide a mean PMI. Out of eleven
tumours six were rejected prior to counting because
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of unsuccessful culture; failure was due to bacterial
contamination, tumour necrosis, or the fact that
some tumours were scirrhous with much stroma
and little epithelial tissue. From the five successful
tumour cultures 45% of explants were unsuitable
for counting, owing to excessive necrosis, or the
presence of only minimal epithelial tumour tissue.
Some of the "unsuitable" tumour explants
comprised normal colonic mucosa only.
The five tumours which were cultured successfully
were all graded histologically as moderately
differentiated adenocarcinomata. Two were from
the sigmoid colon and three from the rectum.
Dukes' staging was as follows: stage A - I tumour;
stage B - 2 tumours; stage C - 1 tumour; stage D -
1 tumour.
The pooled data from all five tumours are shown
in Table I. Figure 1 is a three-dimensional plot of
the relationship between the PMI (%) and
vincristine dose at the three verapamil doses used.
At all three doses there is an increase in metaphase
escape with decreasing dose of vincristine, and this
Table I Mean Post-Metaphase Index with standard
errors.
verapamil dose (1wnoo
vincristine dose
(nmol) 0.0 6.6 13.2
270 4.6+1.3 2.9+0.7 3.3+1.5
540 3.4+ 1.4 2.6+0.6 2.0+0.6
1080 2.4+1.4 0.5+0.3 1.0+0.6
2160 0.5+0.2 0.3+0.3 0.2+0.1
4320 0.0 0.1+0.1 0.3+0.3
corresponds with our previous observations on this
type of data. Verapamil at doses of both 6.6pmol,
and 13.2pumol, comparable with therapeutic plasma
levels up to lOymol (Cantwell et al., 1985) causes a
similar and statistically significant degree of
enhancement of the effect of vincristine. No simple
function of the PMI is linearly related to dose or
log dose of vincristine. Analysis using the GLIM
programme (Baker & Nelder, 1978) and a logistic
transformation of the PMI shows that either dose
of verapamil reduces the PMI by a factor of 0.61
(95% confidence limits 0.47 to 0.78, P<0.001)
independently of the dose of vincristine. A
satisfactory fit (X%=10.91) is found by fitting the
model;
Logit PMI= -6.34-0.50 if verapamil
(s.e. 0.13 P<0.001)
+0.00 if 4320nmol of vincristine
1.01 if 2160nmol of vincristine
1.27 if 1080nmol of vincristine
3.05 if 540nmol of vincristine
3.35 if 270nmol of vincristine
These results provide direct experimental evidence
of the efficacy of pharmacological modification of
primary solid human tumour resistance to
vincristine.
Acquired tumour cell resistance to vincristine is
frequently associated with cross-resistance to anti-
cancer drugs of differing modes of action, notably
adriamycin. This has been termed the pleiotropic
multidrug-resistance phenotype, and in animal
tumour-cell lines appears to be related to the
presence of, and phosphorylation status of, a cell
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Figure 1 Three dimensional plot of the effects ofvincristine and verapamil on the postmetaphase index.VINCRISTINE RESISTANCE OF HUMAN COLON CANCER 139
surface glycoprotein designated P180 (Ling et al.,
1983; Garman et al., 1983). A wide range of
pharmacological modifiers of both vincristine and
adriamycin resistance have been described in a
variety of cell lines of human and animal origin
displaying either acquired or inherent drug
resistance. The pharmacologically induced increase
in tumour-cell sensitivity is accompanied, and
possibly caused, by increased intracytoplasmic
accumulation of the anticancer drug (Tsuruo et al.,
1982). Thus the postulated mechanism of resistance
is the existence of a drug elimination pathway in
the plasma membrane which allows cancer cells to
minimise the intracellular concentration of the
drug. Verapamil is thought to inhibit this pathway.
However, other possible resistance mechanisms,
such as increased intracytoplasmic drug binding
may operate (Beck et al., 1983), and the issue
remains to be resolved. Currently we are using our
organ culture system to investigate the underlying
biochemical basis of vincristine resistance in
primary colonic cancer. This is of crucial
importancc in the longer term development of more
specific and potent modifiers for use in clinical
therapy. Current experimental strategies comprise
empirical selection of potential modifiers of
vincristine resistance, and battery testing against a
range of cell lines of varying drug resistance profile.
This approach has demonstrated that different
agents vary in their ability to act as modifiers
depending upon the particular combination of
cytotoxic drug and cell line tested (Ramu et al.,
1984). It is clear from our results that there is
evidence in vitro that verapamil has a modifying
effect on human primary colonic cancer cells. This
may be of some clinical usefulness in the future, but
verapamil will not necessarily prove to be the most
effective enhancer of vincristine potency.
The verapamil used was kindly donated by Abbott
Laboratories, Queenborough, Kent. We are grateful to
Kathryn Elliott for the preparation of histological sections
and to Brenda Kennedy who typed the manuscript. This
study was supported by a grant from the North of
England Cancer Research Campaign.
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